Reflex Testing for Patients with Suspected Lung Cancer

Author(s):

Zofia Piotrowska, MD, MHS,Martin Dietrich, MD, PhD

Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.

EP: 1.Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing

EP: 2.Concurrent NSCLC Biomarker Testing at Diagnosis

EP: 3.NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing

EP: 4.Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer

EP: 5.Biomarker Testing in Early-Stage NSCLC

Now Viewing

EP: 6.Reflex Testing for Patients with Suspected Lung Cancer

EP: 7.Challenges of NSCLC Biomarker Testing in Clinical Practice

EP: 8.Overcoming Barriers to NSCLC Biomarker Testing

EP: 9.Key Takeaways for Concurrent Biomarker Testing in NSCLC

Please discuss the rationale for conducting liquid-based testing at the time of diagnostic biopsy in patients with suspected advanced NSCLC vs a reflex testing approach. (Thompson JC, et al. JTO Clin Res Rep, 2022)
1. What do prospective data demonstrate?
2. Please comment on the goal of having test results available upon the first patient interaction.
Please discuss data surrounding the impact of concurrent liquid and tissue-based testing on the quality of care in advanced NSCLC. (Maity, et al. JCO Oncology Practice, 2023)
1. What impact does concurrent testing have on time to diagnosis, the need for repeat tissue biopsy, detection of actionable biomarkers?
2. What are some limitations associated with tissue-based testing?
What do data demonstrate regarding the availability of molecular testing results and overall survival of patients with advanced NSCLC? (Aggarwal, et al. JCO Prec Oncol, 2023)